PRNewsWire
02 Sept 2026, 17:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Soleno Therapeutics is facing allegations of concealing significant safety concerns, specifically excess fluid retention, during Phase 3 clinical trials for its DCCR treatment. — Undisclosed safety issues in Phase 3 trials are critical risks that can lead to FDA rejection or severe labeling restrictions, directly threatening the company's primary asset.
-0.80A federal securities lawsuit claims DCCR has materially lower commercial viability and faces risks of reduced patient adoption and prescriber reluctance. — Claims regarding diminished commercial viability directly impact future revenue projections and the long-term valuation of the company.
-0.60Kuehn Law, PLLC is investigating whether officers and directors of Soleno Therapeutics breached their fiduciary duties to shareholders. — While shareholder litigation is common, it introduces legal overhead and potential management instability.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
4h ago
